Sequent Scientific feels confident of managing Covid-19 Pain
Amid concerns of business continuity and loss of sales opportunities - SeQuent Scientific – the owner of India's largest veterinary medicines company Alivira Animal Health – will be shielded from the impact of COVID-19 on the Indian farming sector, as the majority of its sales are via exports. Therefore, the company expects the lockdown to have "little impact" on its key markets.
Nevertheless, SeQuent has put in place a business continuity plan to help it deal with the consequences of the crisis. The firm's factories across worldwide locations are working with reduced staff, while all non-essential employees have been working remotely.
The firm stated: "We have optimized our workloads and made alternate logistics arrangements across all factories to ensure our continued focus and commitment to our clients and target geographies."
Alivira has put the capacity expansion project at its German plant on hold, while improvements to its Vizag facility have been "suitably moderated to minimize human presence at the site, without impacting growth prospects".
SeQuent added: "On the supply chain side, we are fully covered for all key materials for both our active pharmaceutical ingredients and formulation units, and the only challenge we face is logistics disruption. We are continuously and pro-actively engaged with the relevant authorities who are helping us to the best of their abilities in keeping the operations ongoing."
Many of the other leading animal health businesses are privately-owned and have yet to reveal the full, or impending, impact of COVID-19 on their businesses.